Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379536 | 0.90 | KMT2A (0.53) | LMNAL3MBTL1KMT2ASMN1; SMN2ALOX5 | |
| SCHEMBL4338001 | 0.83 | LMNA (0.46) | LMNAL3MBTL1KMT2ASMN1; SMN2ALOX5 | |
| SCHEMBL3370422 | 0.82 | MRGPRX4 (0.49) | LMNAL3MBTL1SMN1; SMN2FFAR1 | |
| SCHEMBL5360486 | 0.79 | KMT2A (0.54) | L3MBTL1KMT2ASMN1; SMN2ALOX5MEN1 | |
| SCHEMBL3485036 | 0.79 | KMT2A (0.56) | LMNAL3MBTL1KMT2ASMN1; SMN2ALOX5 | |
| SCHEMBL20604383 | 0.78 | KMT2A (0.62) | LMNAKMT2ASMN1; SMN2ALOX5MEN1 | |
| SCHEMBL20604382 | 0.78 | KMT2A (0.62) | LMNAKMT2ASMN1; SMN2ALOX5MEN1 | |
| SCHEMBL5358921 | 0.78 | LMNA (0.60) | LMNAL3MBTL1SMN1; SMN2ALOX5MAOB | |
| SCHEMBL16797634 | 0.78 | KMT2A (0.55) | LMNAL3MBTL1KMT2ASMN1; SMN2ALOX5 | |
| SCHEMBL5772077 | 0.78 | KMT2A (0.62) | LMNAKMT2ASMN1; SMN2ALOX5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | LMNA 3790/4885L3MBTL1 3856/4885KMT2A 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.